Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 79,57 € (+2,57 %). La mediana es de 82,87 € (+6,82 %).
| Comprar |
9 |
| Mantener |
2 |
| Vender |
1 |
Noticias Ir al feed de noticias
Solventum sharpens medtech strategy and plans spin-off of HIS division
Solventum announced at the Wells Fargo healthcare conference that it will focus more on medical technology and spin off its Healthcare Information Services (HIS) unit, with options including sale, spin-off or partnership. The company raised its forecast for organic growth in 2026 to 2.5–3.0% but expects a near-term margin dilution of around 400 basis points from the HIS separation. MedSurg and dental (over 80% of the business) remain the main growth drivers; about 20 new products are planned by Q1 2028, with a target of 4–5% organic growth for 2028 (ex-HIS). » Más en de.investing.com
Solventum reaches 52-week high at $88.21
Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The health‑technology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fair‑value estimate signals as a slight overvaluation. » Más en de.investing.com
UBS upgrade drives Solventum stock sharply higher
UBS upgraded Solventum from “Neutral” to “Buy” and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 1935,55 M | 5,57 % |
| Beneficio bruto | 1126,81 M | 13,03 % |
| Beneficio neto | 80,61 M | 5,57 % |
| EBITDA | 150,71 M | 45,84 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 13,77 mil M € |
Número de acciones | 173,17 M |
Máximo/mínimo de 52 semanas | 82,14 € - 54,41 € |
| Dividendos | No |
Beta | 0,69 |
Ratio P/E | 11,09 |
Ratio PEG | 0,04 |
Ratio P/B | 3,30 |
Ratio P/S | 1,90 |
Perfil de la empresa
Die Solventum Corporation, ein Unternehmen der Gesundheitsbranche, entwickelt, produziert und vertreibt ein Portfolio von Lösungen für kritische Kunden- und Patientenbedürfnisse. Das Unternehmen ist in vier Segmenten tätig: Medsurg, Dental Solutions, Health Information Systems sowie Purification and Filtration. Das Segment Medsurg bietet unter anderem Lösungen für die erweiterte Wundversorgung, das Management von Infusionsstellen, die Sicherstellung der Sterilisation, das Temperaturmanagement, chirurgisches Zubehör, Stethoskope und medizinische Elektroden an. Das Segment Dental Solutions bietet ein umfassendes Angebot an zahnmedizinischen und kieferorthopädischen Produkten wie Brackets, Aligner, Restaurationszemente und Haftmittel. Das Segment Health Information Systems bietet Softwarelösungen an, darunter computergestützte Arztdokumentation, Automatisierung von Direct-to-Bill und Kodierung, Klassifizierungsmethoden, Spracherkennung und Datenvisualisierungsplattformen. Das Segment Purification and Filtration bietet Reinigungs- und Filtrationstechnologien an, darunter Filter, Reinigungsanlagen, Kartuschen und Membranen. Das Unternehmen wurde im Jahr 2023 gegründet und hat seinen Sitz in Saint Paul, Minnesota.
| Nombre | Solventum |
| CEO | Bryan C. Hanson |
| Sede | Eagan,
mn Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 21/07/2014 |
| Empleados | 20.584 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | SOLV |
Frankfurt | KB7.F |
Düsseldorf | KB7.DU |
München | KB7.MU |
